PHARMO, a Lumanity business, is a Gold conference sponsor and exhibitor at the International Society for Pharmacoepidemiology 2025 annual meeting in Washington, D.C. Visit our booth and check out our presentations. This conference brings together more than 1,400 leaders representing industry, service providers, government/regulatory agencies, academia, consultants and students – all dedicated to advancing the health of the public.
Schedule time to meet with our attending staff by reaching out to contact@lumanity.com
Check out all of the presentations where we are listed as author or co-author:
- Paternal Linkage in the PHARMO Data Network: Assessing the Impact of Paternal Drug Exposure on Child Health Outcomes – Poster B-276
- Assessing the risk of angioedema in adult sacubitril/valsartan users with heart failure: Results from a post-authorization safety study in seven European electronic healthcare databases – Poster C-237
- Investigating potential drug-drug-interactions between sacubitril/valsartan and statins and the risk of myotoxicity, hepatotoxicity or acute pancreatitis: a post-authorisation safety study in 7 European healthcare databases – Poster SLB-036
- Implementing and Validating an Algorithm for Identifying ATTR-CM patients in the PHARMO Data Network – Poster SLC-037
- Incidence of post-partum hemorrhage and amount of blood loss in the Netherlands – Poster B-239
- Studying paternal drug exposures and offspring outcomes: feasibility assessment of large European databases – Poster A-023
- Preliminary results from a European post authorization study to assess the safety of Paxlovid among patients with moderate or severe hepatic or renal impairment – Poster B-093
- Preliminary Results from a European Post-Authorization Study to Assess the Safety of Paxlovid in Pregnancy – Poster B-257
- 2024 interim results from the VAC4EU post-authorisation safety study (PASS) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) in Europe – Poster A-339
- Evaluating the Diagnostic Accuracy of Adverse Events of Special Interest Following Janssen COVID-19 Vaccine (JCOVDEN) Using the VAC4EU Validation Pipeline – Poster A-338
- Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study – Poster SLC-053
Visit us at booth 412 and connect with our experts attending ICPE 2025:
